Navigation Links
Study pinpoints new role of molecule in the health of body's back-up blood circulation
Date:5/25/2010

CHAPEL HILL When the arteries delivering oxygen to our vital organs are obstructed by atherosclerosis or clots, the result is almost always a stroke, heart attack or damage to a peripheral tissue such as the legs (peripheral artery disease). But the severity of tissue injury or destruction from a choked-off blood supply varies from person to person, and may depend in large part on whose circulatory system has the best back-up plan to provide alternate routes of circulation.

This "back-up system" called the collateral circulation involves a small number of tiny specialized blood vessels, called collaterals, that can enlarge their diameters enough to carry significant flow and thus bypass a blockage.

Researchers at the University of North Carolina at Chapel Hill School of Medicine have now discovered that the abundance of these vessels in a healthy individual and their growth or remodeling into "natural bypass vessels" depends on how much of a key signaling molecule -- called nitric oxide -- is present.

The study, conducted in animal models, suggests that nitric oxide not only is critical in maintaining the number of collateral vessels while individuals are healthy. It also is key in the amount of collateral vessel remodeling that occurs when obstructive disease strikes.

The research findings recently appeared online in the journal Circulation Research and will be published in the print edition on June 25th. They could one day enable researchers to predict people's risk for catastrophic stroke, myocardial infarction, or peripheral artery disease. Such knowledge could inform individuals with poor collateral capacity to adopt a lifestyle that can help reduce their chances of getting diseases that could further lower their number of collateral vessels.

"If you've got a good number of these natural bypass vessels, you have something of an 'insurance policy' that favors you suffering less severe consequences if you get atheroscle
'/>"/>

Contact: Les Lang
llang@med.unc.edu
919-966-9366
University of North Carolina School of Medicine
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. Study begins to reveal clues to the cause and progression of sepsis
4. Clones on task serve greater good, evolutionary study shows
5. New study warns limited carbon market puts 20 percent of tropical forest at risk
6. New study examines how rearing environment can alter navigation
7. Study links cat disease to flame retardants in furniture and to pet food
8. New continent and species discovered in Atlantic study
9. Study shows link between alcohol consumption and hiv disease progression
10. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
11. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study pinpoints new role of molecule in the health of body's back-up blood circulation
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting its ... and has launched a new marketing campaign to solidify ... (CLO).  The new campaign focuses on First ... and shipments. The first headline in the ... Marken,s priorities with its client,s priorities. Marken recognizes the ...
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... which trauma and burn patients are most likely to ... range of experimental clinical settings ?an important hurdle to ... rooms and intensive care units. , In a report ... National Academy of Sciences, researchers from eight institutions, including ...
... of California, San Diego (UCSD) have found that Lafora disease, ... the age of 30, can be caused by mutations in ... These findings are reported in the current issue of Proceedings ... is characterized by normal development for the first decade of ...
... comparing, for the first time, breast cancers from Nigeria, ... African ancestry are more likely to be diagnosed with ... of European ancestry. , Researchers from the University of ... in Nigeria and the University of North Carolina, found ...
Cached Biology News:Doctors closer to using gene analysis to help trauma patients 2Doctors closer to using gene analysis to help trauma patients 3UCSD research reveals mechanism involved with type of fatal epilepsy 2Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
(Date:3/4/2015)... 4, 2015 Launched by ... in December 2011, ,SARAH, - the ... microspheres versus sorafenib in advanced hepatocellular carcinoma (HCC) has ...   SARAH, a large French study of ... or HCC) has completed patient enrolment, exceeding its 400-patient ...
(Date:3/3/2015)... - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a ... target the underlying mechanisms of cancer, today reported financial ... 31, 2014. Effective July 17, 2014, the ... to December 31. As a result of that change, ... quarter and the seven months ended December 31, 2014, ...
(Date:3/3/2015)... 03, 2015 Experts and industry insiders ... one event: the Alltech REBELation exploring innovation, inspiration and ... Now in its 31st year, Alltech’s annual international conference ... and the opportunity to join the REBELation at an ... 11:59 p.m. EST, at which point the standard early ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... Family practice, inevitably the most prominent healthcare specialty, is ... increase in the number of patients, with Texas, Florida and ... Family practice physicians in the US. MBC, with a huge ... in Dallas, expects to fulfill the increasing demand for administrative ...
... ReportsnReports   announces it will carry ... markets (industries) of Belgium in its store A. ... market is expected to grow from $99.6 billion in 2010 to $162.2 ... EMR is expected to be the highest growing market with ...
... and TOKYO, Aug. 15, 2011 A new post-hoc ... TRITON-TIMI 38 study – those identified as the "core ... (in combination with aspirin) was associated with a 26 ... of cardiovascular death, myocardial infarction or stroke, compared to ...
Cached Biology Technology:MBC has the Highest Number of Medical Billers and Coders in Dallas, Texas Servicing Primary Healthcare Physicians 2MBC has the Highest Number of Medical Billers and Coders in Dallas, Texas Servicing Primary Healthcare Physicians 3MBC has the Highest Number of Medical Billers and Coders in Dallas, Texas Servicing Primary Healthcare Physicians 4MBC has the Highest Number of Medical Billers and Coders in Dallas, Texas Servicing Primary Healthcare Physicians 5ReportsnReports - Healthcare IT Market, Electric Buses & Taxis, Belgium Market Research 2ReportsnReports - Healthcare IT Market, Electric Buses & Taxis, Belgium Market Research 3ReportsnReports - Healthcare IT Market, Electric Buses & Taxis, Belgium Market Research 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 3Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 6Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 7Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 8
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
... Fluor 488 Cytochrome c Apoptosis Detection Kit ... detect cytochrome c in fixed cells. The ... antibody and an Alexa Fluor 488 dye-labeled ... bright green fluorescence that is compatible with ...
MOUSE ANTI NEUROFILAMENTS 140+160 KD...
Biology Products: